» Articles » PMID: 21225319

Barriers to Non-viral Vector-mediated Gene Delivery in the Nervous System

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 2011 Jan 13
PMID 21225319
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Efficient methods for cell line transfection are well described, but, for primary neurons, a high-yield method different from those relying on viral vectors is lacking. Viral transfection has several drawbacks, such as the complexity of vector preparation, safety concerns, and the generation of immune and inflammatory responses when used in vivo. However, one of the main problems for the use of non-viral gene vectors for neuronal transfection is their low efficiency when compared with viral vectors. Transgene expression, or siRNA delivery mediated by non-viral vectors, is the result of multiple processes related to cellular membrane crossing, intracellular traffic, and/or nuclear delivery of the genetic material cargo. This review will deal with the barriers that different nanoparticles (cationic lipids, polyethyleneimine, dendrimers and carbon nanotubes) must overcome to efficiently deliver their cargo to central nervous system cells, including internalization into the neurons, interaction with intracellular organelles such as lysosomes, and transport across the nuclear membrane of the neuron in the case of DNA transfection. Furthermore, when used in vivo, the nanoparticles should efficiently cross the blood-brain barrier to reach the target cells in the brain.

Citing Articles

Dendrimers-Novel Therapeutic Approaches for Alzheimer's Disease.

Mroziak M, Kozlowski G, Kolodziejczyk W, Pszczolowska M, Walczak K, Beszlej J Biomedicines. 2024; 12(8).

PMID: 39200363 PMC: 11351976. DOI: 10.3390/biomedicines12081899.


Allogenic microglia replacement: A novel therapeutic strategy for neurological disorders.

Rao Y, Peng B Fundam Res. 2024; 4(2):237-245.

PMID: 38933508 PMC: 11197774. DOI: 10.1016/j.fmre.2023.02.025.


Recent advances in the development of poly(ester amide)s-based carriers for drug delivery.

Xie R, Li J, Zhao M, Wu F Saudi Pharm J. 2024; 32(7):102123.

PMID: 38911279 PMC: 11190562. DOI: 10.1016/j.jsps.2024.102123.


Brain-targeted drug delivery - nanovesicles directed to specific brain cells by brain-targeting ligands.

Moreira R, Nobrega C, de Almeida L, Mendonca L J Nanobiotechnology. 2024; 22(1):260.

PMID: 38760847 PMC: 11100082. DOI: 10.1186/s12951-024-02511-7.


Engineered smart materials for RNA based molecular therapy to treat Glioblastoma.

Singh R, Mondal I, Janjua T, Popat A, Kulshreshtha R Bioact Mater. 2023; 33:396-423.

PMID: 38059120 PMC: 10696434. DOI: 10.1016/j.bioactmat.2023.11.007.


References
1.
Vasir J, Labhasetwar V . Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev. 2007; 59(8):718-28. PMC: 2002520. DOI: 10.1016/j.addr.2007.06.003. View

2.
Mukherjee S, Ghosh R, Maxfield F . Endocytosis. Physiol Rev. 1997; 77(3):759-803. DOI: 10.1152/physrev.1997.77.3.759. View

3.
Binder H, Lindblom G . Charge-dependent translocation of the Trojan peptide penetratin across lipid membranes. Biophys J. 2003; 85(2):982-95. PMC: 1303219. DOI: 10.1016/S0006-3495(03)74537-8. View

4.
Posadas I, Guerra F, Cena V . Nonviral vectors for the delivery of small interfering RNAs to the CNS. Nanomedicine (Lond). 2010; 5(8):1219-36. DOI: 10.2217/nnm.10.105. View

5.
Ma K, Hu M, Qi Y, Qiu L, Jin Y, Yu J . Structure-transfection activity relationships with glucocorticoid-polyethyl-enimine conjugate nuclear gene delivery systems. Biomaterials. 2009; 30(22):3780-9. DOI: 10.1016/j.biomaterials.2009.03.042. View